A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Status:
Completed
Trial end date:
2021-04-29
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug
LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.